Targagenix
Novel cancer therapy targeting chemotherapy-resistant tumors
About Targagenix
TargaGenix, Inc. is a biotechnology company founded in June 2013 as a spinout from Stony Brook University. The company is focused on developing novel therapies to treat cancer, specifically targeting cancer stem cells and bulk tumor cells that are resistant to existing chemotherapy.
The company's lead product is a third-generation taxane known as DHA-SBT-1214. This compound was the result of over a decade of research led by Dr. Iwao Ojima at Stony Brook University's Institute of Chemical Biology & Drug Discovery to find molecules effective against drug-resistant tumors. The agent has shown promise in preclinical models by eliminating tumors and has been licensed to TargaGenix to advance its development towards clinical use. A key feature is its formulation within a fatty-acid based nanoemulsion, which reduces toxicity and improves how the drug is absorbed and distributed in the body.
The President and CEO is James Egan, who has a background in both academic and commercial drug development and holds a PhD in Molecular Pharmacology from Stony Brook University. The company's business model involves advancing its compounds through clinical trials to gain regulatory approval, with the aim of partnering with larger pharmaceutical firms for commercialization. TargaGenix has received investment to advance its lead compound, NE-DHA-SBT-1214, to market as a potential treatment for colorectal cancer and other solid tumors, with plans to test it as both a standalone drug and in combination with other immuno-oncology agents.
Source: Dealroom company dataNews
Open roles
Targagenix in the Town of Brookhaven ecosystem
The Targagenix office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Accelerate New York Seed Fund- ACAJI Capital
Series A1 investor entered at this stage
DeBere Capital Partners
Series B and later1 investor entered at this stage
TVM Capital Life Science
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Targagenix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Targagenix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
